Table 2

Descriptions of values and preferences studies

StudyLocationPopulation descriptionStudy designMethodsSample size (n)
End users
Begnel et al24Kenya: Homa Bay, Kisii, Kisumu, Migori, Nyamira, and SiayaAdults aged 18+ yearsQuantitativeCross-sectional SMS survey2498
Crawford et al26USA: Atlanta area, GeorgiaAdult MSMQualitativeSemi-structured in-depth interviews8
Crawford et al25USA: Atlanta, GeorgiaHIV− MSM not using PrEPQuantitativeCross-sectional survey259
Havens et al21USA: Omaha, NebraskaPrEP usersQuantitativeCross-sectional survey in case study project60
Lutz et al27USA: ArizonaHIV− PrEP clients and HIV+ ART clientsQuantitativeCross-sectional survey49
Minnis et al28South Africa: Nyanga and Masiphumelele, near Cape TownPrEP-eligible youth aged 18–24 yearsQuantitativeDiscrete choice experiment807
Zhu et al29USA: Washington, District of Columbia and MarylandHIV− adultsQuantitativeCross-sectional survey117
Pharmacists and other professional stakeholders
Broekhuis et al30USA: Nebraska and IowaPharmacistsQuantitativeCross-sectional online survey140
Crawford et al26USA:
Atlanta area, Georgia
PharmacistsQualitativeSemi-structured in-depth interviews6
Havens et al21USA:
Omaha, Nebraska
PharmacistsQuantitativeCross-sectional survey in case study project7
Hopkins et al31USA:
Atlanta, Georgia
Pharmacists and pharmacy techniciansQualitativeSemi-structured in-depth interviews13
Koester et al32USA: CaliforniaPharmacists, physicians, pharmacy representativesQualitativeSemi-structured phone interviews11
Ortblad et al33Kenya:
Nairobi
Stakeholders from PrEP regulatory, professional, healthcare service delivery, civil society and research organisationsQualitativeFocus groups36
  • ART, antiretroviral therapy; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis.